Bcr/Abl activates transcription of the Bcl-X gene through STAT5GESBERT, Franck; GRIFFIN, James D.Blood. 2000, Vol 96, Num 6, pp 2269-2276, issn 0006-4971Article

The roles of FLT3 in hematopoiesis and leukemiaGILLILAND, D. Gary; GRIFFIN, James D.Blood. 2002, Vol 100, Num 5, pp 1532-1542, issn 0006-4971, 11 p.Article

Role of FLT3 in leukemiaGILLILAND, D. Gary; GRIFFIN, James D.Current opinion in hematology. 2002, Vol 9, Num 4, pp 274-281, issn 1065-6251Article

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL⁺ leukemiasWEISBERG, Ellen; CATLEY, Laurie; HALL-MEYERS, Elizabeth et al.Blood. 2007, Vol 109, Num 5, pp 2112-2120, issn 0006-4971, 9 p.Article

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemiaLEVINE, Ross L; LORIAUX, Marc; FLORES, Nikki J et al.Blood. 2005, Vol 106, Num 10, pp 3377-3379, issn 0006-4971, 3 p.Article

c-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functionsMA, Patrick C; KIJIMA, Takashi; MAULIK, Gautam et al.Cancer research (Baltimore). 2003, Vol 63, Num 19, pp 6272-6281, issn 0008-5472, 10 p.Article

Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cellsSATTLER, Martin; PRIDE, Yuri B; QUINNAN, Laura R et al.Oncogene (Basingstoke). 2002, Vol 21, Num 9, pp 1423-1433, issn 0950-9232Article

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein : biological and clinical implicationsTUVESON, David A; WILLIS, Nicholas A; JACKS, Tyler et al.Oncogene (Basingstoke). 2001, Vol 20, Num 36, pp 5054-5058, issn 0950-9232Article

Phosphatidyl inositol signaling by BCR/ABL : opportunities for drug developmentGRIFFIN, James D.Cancer chemotherapy and pharmacology. 2001, Vol 48, pp S11-S16, issn 0344-5704, SUP1Conference Paper

BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repairFERNANDES, Margret S; REDDY, Mamatha M; GONNEVILLE, Jeffrey R et al.Blood. 2009, Vol 114, Num 9, pp 1813-1819, issn 0006-4971, 7 p.Article

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis studyRAY, Arghya; COWAN-JACOB, Sandra W; MANLEY, Paul W et al.Blood. 2007, Vol 109, Num 11, pp 5011-5015, issn 0006-4971, 5 p.Article

Molecular mechanisms of transformation by the BCR-ABL oncogeneSATTLER, Martin; GRIFFIN, James D.Seminars in hematology. 2003, Vol 40, Num 2, pp 4-10, issn 0037-1963, 7 p., SUP2Conference Paper

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitroMOW, Benjamin M. F; CHANDRA, Joya; TEFFERI, Ayalew et al.Blood. 2002, Vol 99, Num 2, pp 664-671, issn 0006-4971Article

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironmentLIN, Boris; PODAR, Klaus; WEISBERG, Ellen et al.Cancer research (Baltimore). 2002, Vol 62, Num 17, pp 5019-5026, issn 0008-5472, 8 p.Article

MAML1, a human homologue of Drosophila Mastermind, is a transcriptional co-activator for NOTCH receptorsWU, Lizi; ASTER, Jon C; BLACKLOW, Stephen C et al.Nature genetics. 2000, Vol 26, Num 4, pp 484-489, issn 1061-4036Article

Tyrosine kinase oncogenes in normal hematopoiesis and hematological diseaseSCHEIJEN, Blanca; GRIFFIN, James D.Oncogene (Basingstoke). 2002, Vol 21, Num 21, pp 3314-3333, issn 0950-9232, 20 p.Article

The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factorsOKUDA, Keiko; SATO, Yuko; SONODA, Yoshiaki et al.International journal of hematology. 2004, Vol 79, Num 2, pp 138-146, issn 0925-5710, 9 p.Article

A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic TargetsADAMIA, Sophia; HAIBE-KAINS, Benjamin; GALINSKY, Ilene et al.Clinical cancer research (Print). 2014, Vol 20, Num 5, pp 1135-1145, issn 1078-0432, 11 p.Article

Development of 'DFG-out' inhibitors of gatekeeper mutant kinasesHWAN GEUN CHOI; JIANMING ZHANG; WEISBERG, Ellen et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 16, pp 5297-5302, issn 0960-894X, 6 p.Article

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignanciesWADLEIGH, Martha; DEANGELO, Daniel J; GRIFFIN, James D et al.Blood. 2005, Vol 105, Num 1, pp 22-30, issn 0006-4971, 9 p.Article

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesJING CHEN; LEE, Benjamin H; MOORE, Sandra et al.Oncogene (Basingstoke). 2005, Vol 24, Num 56, pp 8259-8267, issn 0950-9232, 9 p.Article

Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemiaCOOLS, Jan; MENTENS, Nicole; FURET, Pascal et al.Cancer research (Baltimore). 2004, Vol 64, Num 18, pp 6385-6389, issn 0008-5472, 5 p.Article

An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kitXIANMING DENG; WENJUN ZHOU; WEISBERG, Ellen et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 14, pp 4579-4584, issn 0960-894X, 6 p.Article

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitorsNELSON, ErikA; WALKER, Sarah R; EBERT, Benjamin L et al.Blood. 2011, Vol 117, Num 12, pp 3421-3429, issn 0006-4971, 9 p.Article

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsWEISBERG, Ellen; HWAN GEUN CHOI; FLETCHER, Jonathan A et al.Blood. 2010, Vol 115, Num 21, pp 4206-4216, issn 0006-4971, 11 p.Article